Kardio-Blogger Dr. John Mandrola: Die spannendsten Studien beim AHA 2020
Medscape,
Medscape -Kardiologie-Blogger berichtet über ausgewählte Studien, die auf dem diesjährigen virtuellen Kongress der American…
Mandrola Previews AHA 2020
Medscape,
Finally, THE Answer on Statin Side Effects Well over 100,000 patients have been enrolled in blinded randomized controlled…
Nov 6 2020 This Week in Cardiology
Medscape,
Please note that the text below is not a full transcript and has not been copyedited.
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Jotup,
The second interim analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as…
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Finanzen.ch,
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb.
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
ProfitQuotes.com,
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 26, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN)…
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Ariva,
Amgen Aktionäre handeln die Aktien von Amgen für einmalig nur 4 Euro HIER GRATIS ANSCHAUEN PR Newswire THOUSAND OAKS, Calif.…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Wall Street Online Denmark,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Ticker Tech,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
MarketScreener,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Benzinga,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Morning Star,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
AP News,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
PR Newswire,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
GlobeNewswire,
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue…